All HHS Contracts — June 10, 2026

Tunnell Consulting Inc. secured a $92.8 million delivery order from BARDA (HHS) for advanced scientific subject matter expertise in biotech and biopharmaceutical R&D, with options extending to 2035 and a total potential value of $660.2 million. This signals sustained government commitment to biodefense and pandemic preparedness, a likely growth area for professional services firms in the sector.

The $125.5 million cost-no-fee contract from the CDC for the World Trade Center Health Program Clinical Center of Excellence has ended (potential end 2022-09-30), with only $32.9 million outlayed—26% of the total obligation. This indicates limited future revenue from this award and potential under-execution.

The Tunnell Consulting contract uses a labor-hours pricing type, meaning the government pays for actual hours worked, shifting cost risk to the contractor if hours exceed estimates. Margins are typically lower than fixed-price contracts, and the medium contract risk rating reflects this uncertainty.

Icahn School of Medicine's CDC contract has only $32.9M outlayed out of $125.5M total obligation (26% outlay rate), suggesting potential under-execution or budget constraints that could affect follow-on awards.

Tunnell Consulting is a private company, limiting direct investment avenues. Investors cannot buy shares, and any acquisition or IPO is uncertain.

The Tunnell contract's $660.2M potential value depends on option exercises through 2035, which are subject to future budget cycles and political priorities. A shift in pandemic preparedness funding could reduce realized value.

Tunnell Consulting's BARDA contract positions it as a key player in biodefense R&D support, a growth area driven by pandemic preparedness and bioterrorism concerns. Competitors in this space may benefit from similar awards.

The CDC's World Trade Center Health Program is a long-term federal initiative, and re-competes for Clinical Center of Excellence contracts could provide opportunities for other healthcare services providers.

Tunnell Consulting's $92.8M BARDA delivery order (potential $660.2M) underscores sustained government investment in biotech R&D and medical countermeasure development, a theme reinforced by BARDA's mission within HHS. This is a civilian-driven but defense-adjacent sector.

Icahn School of Medicine's $125.5M cost-no-fee CDC contract provides stable but zero-profit revenue, highlighting the low-margin nature of certain HHS healthcare services awards. This limits financial upside for contractors in this niche.

{"entity"=>"Tunnell Consulting Inc.", "reason"=>"Private company with a $660.2M potential BARDA contract; any acquisition or IPO would create direct investment opportunity.", "trigger"=>"Acquisition announcement or IPO filing"}

{"entity"=>"CDC World Trade Center Health Program", "reason"=>"Icahn's contract has ended; re-competes for Clinical Center of Excellence could open opportunities for other healthcare services firms.", "trigger"=>"Re-compete solicitation release"}

{"entity"=>"BARDA", "reason"=>"Tunnell's contract is a delivery order under a larger IDIQ; similar awards to competitors could signal market share dynamics.", "trigger"=>"Option exercise announcements or new delivery orders to other firms"}